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GGG GCC  (G4C2) repeat expansion in the first intron of 
C9ORF72 is the most common genetic cause of amyotrophic 
lateral sclerosis (ALS) and frontotemporal dementia (FTD) 
[6, 11]. Brain tissues from affected individuals show char-
acteristic nuclear RNA foci containing the expanded repeat 
RNAs, as well as neuronal inclusions containing dipeptide 
repeat (DPR) proteins [poly(GA), poly(GP), poly(GR), 
poly(PR), and poly(PA)] resulting from the translation of 
both sense and antisense repeat RNAs in all reading frames 
[4, 9, 14]. Although reduced C9ORF72 protein function may 
contribute to disease [10], the more likely drivers of dis-
ease are mechanisms related to a gain of toxic function [7]. 
Currently, intense efforts are being made to identify disease 
mechanisms amenable for the development of therapeutic 
strategies. One promising avenue would be to prevent the 
production of the expanded repeat RNAs, such as by anti-
sense oligonucleotides [5]. Here, we tested another potential 
therapeutic approach: CRISPR/Cas9-based targeting of the 
promoter region.
In ALS and FTD patients, transcription initiated at exon-
1a of C9ORF72 generates RNA species containing  G4C2 
repeat expansions that are in turn translated into three DPR 
proteins, poly(GA), poly(GP), and poly(GR). Thus, we first 
used reporter constructs to identify the promoter sequence 
5′ to exon-1a that is responsible for transcription initiation 
of expanded repeat RNA. We cloned the 435 nucleotides 
(nt) upstream of the predicted transcription initiation site, as 
well as several truncated fragments of the 435-nt sequence, 
into a luciferase reporter vector (Fig. 1a) and expressed all 
the constructs in HEK293 cells. Deletion of the first 301 nt 
did not reduce the relative expression of the reporter gene. 
However, deleting the remaining 134 nt abolished luciferase 
expression (Fig. 1a), indicating that the core promoter ele-
ments are located in this region. To further characterize this 
sequence, we also tested a construct lacking the first 394 
nt and one lacking the remaining 41 nt. Each of these dele-
tions reduced the relative luciferase expression, indicating 
that both constructs lacked a portion of sequence required 
for reporter gene expression (Fig. 1a). These experiments 
indicate that the last 134 nt sequence contains the minimal 
promoter necessary to drive expression of  G4C2 repeat-con-
taining C9ORF72 transcripts.
To investigate how this deletion affects the production 
of RNAs containing  G4C2 repeat expansions in C9ORF72 
human neurons, we used CRISPR-Cas9 technology to gen-
erate a similar deletion 5′ to exon-1a of C9ORF72 in an 
induced pluripotent stem cell (iPSC) line containing ~ 1000 
copies of the  G4C2 repeats [2] (Figs. 1b, c; S1). We selected 
two iPSC lines containing the promoter deletion and differ-
entiated them and the parental iPSC line into ChAT-positive 
motor neurons (see Suppl. Information). As expected, the 
promoter deletion eliminated the expression of C9ORF72-
Variant 3 (V3), whose transcription starts on exon-1a 
(Fig. 1b, d). In contrast, the RNA level of C9ORF72-V2, 
whose translation starts on exon 1b, or the expression of 
C9ORF72-antisense RNA, was not significantly affected 
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(Fig. 1e–f), consistent with the fact that these transcripts 
have their own promoters [6]. In iPSCs and motor neurons 
harboring the promoter deletion, we detected a reduction in 
the levels of full-length C9ORF72 protein (Figs. 1g; S2), 
likely due to loss of C9ORF72-V3 expression.
Since RNAs containing the  G4C2 repeat expansion lead 
to the production of DPR proteins, we next measured DPR 
protein levels in parental and promoter deletion motor neu-
ron cultures using Meso Scale Discovery immunoassays. We 
found that expression of poly(GA), poly(GP), and poly(GR) 
was almost completely abolished in the motor neuron cul-
tures harboring the promoter deletion (Fig. 2a–c). We then 
examined the functional consequence of reducing DPR 
levels in these neurons, using axonal degeneration as our 
Fig. 1  Deletion of the 
C9ORF72 promoter region. 
a Schematic of the different 
promoter deletions analyzed in 
the luciferase reporter assay and 
quantification of the relative 
expression of firefly lucif-
erase (FLuc)/renilla luciferase 
(RLuc) in HEK293 cells (n = 3 
independent transfections). b 
Schematic of the C9ORF72 
locus in parental and promoter 
deletion iPSC-derived neurons. 
Arrows indicate the site of 
transcription initiation for the 
different variants. Only variants 
containing exon 1a are expected 
to be affected by the deletion; 
the variant containing exon 1b 
is predicted to use a different 
promoter. c CRISPR-edited 
iPSC lines are homozygous for 
the 140-bp deletion as indicated 
by the PCR analysis. d–f 
Four-week-old motor neurons 
from parental and promoter 
deletion lines were analyzed for 
expression of C9ORF72-V3, 
C9ORF72-V2, and C9ORF72-
antisense RNAs (n = 3 
independent differentiations). 
g C9ORF72 protein levels in 
4-week-old parental and pro-
moter deletion motor neurons 
(n = 3 independent differentia-
tions). Values are mean ± SEM. 
*p < 0.05, **p < 0.01, 
***p < 0.001 (a, e–g, one-way 
ANOVA; d, Welch’s t test). ns 
not significant
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scoring metric as we reported recently [12]. Deletion of the 
promoter region prevented the increase in axonal degenera-
tion of parental motor neurons upon withdrawal of neuro-
trophic factors for 2 weeks (Figs. 2d, e; S3), a phenotype 
we previously described in neurons differentiated from two 
pairs of isogenic C9ORF72 iPSC lines [12]. The promoter 
deletion also prevented upregulation of the expression of the 
heat shock protein HSPA1B mRNA (Fig. 2f), a phenotype 
detected in ALS/FTD patient brain tissues and C9ORF72 
iPSC-derived motor neurons [3, 8].
Our results indicate that deletion of the 134 nt mini-
mal promoter 5′ to exon-1a in C9ORF72 prevents both 
Fig. 2  Effects of C9ORF72 promoter deletion in iPSC-derived neu-
rons. a–c Poly(GA), poly(GP), and poly(GR) levels in 1.5-month-old 
parental neurons, neurons without repeats, and promoter deletion 
motor neurons (n = 3 independent differentiations) were measured 
with Meso Scale Discovery immunoassays. The poly(GA) assay 
was done in a blinded manner at Biogen. d Representative immuno-
fluorescence images of the axonal degeneration assay done with the 
marker βΙΙΙ-tubulin  (TUJ1+), which revealed swollen varicosities and 
axonal fragments. Arrowheads indicate fragmented axons. e Axonal 
degeneration assessed by measuring the ratio of fragmented axons 
over the total  TUJ1+ area 2 weeks after withdrawal of neurotrophic 
factors. Six to eight randomly selected fields were analyzed for each 
condition and each neuronal culture. Each independent data point 
represents one field, (n = 3 independent differentiations). f Relative 
expression of HSPA1B in 10-week-old motor neuron cultures (n = 3 
independent differentiations). Values are mean ± SEM. *p < 0.05, 
***p < 0.001 (one-way ANOVA, Dunnett’s multiple comparisons 
test)
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the production of sense RNAs containing expanded  G4C2 
repeats and the activation of downstream neurodegeneration 
pathways. These findings also suggest that sense repeat RNA 
and its translation products are responsible for the observed 
neurodegenerative phenotypes, at least in this experimen-
tal system. The promoter deletion also partially decreased 
C9ORF72 protein levels. However, in the absence of DPR 
proteins, loss of C9ORF72 does not cause neurodegeneration 
in mice or iPSC-derived motor neurons [1, 10]. Improved 
versions of the CRISPR interference are now being tested 
in vivo to silence gene transcription without cutting genomic 
DNA [13]. Thus, our proof-of-concept study suggests that 
CRISPR/Cas9-based targeting of the promoter region to 
eliminate sense repeat RNA and its toxic translation prod-
ucts may be a potentially useful therapeutic approach for 
C9ORF72-ALS/FTD, especially before significant accumu-
lation of DPR proteins.
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